Avid BioservicesCDMO Market cap $678M
About: Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Employees: 371
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
3% more funds holding
Funds holding: 165 [Q1] → 170 (+5) [Q2]
4% more capital invested
Capital invested by funds: $446M [Q1] → $465M (+$18.8M) [Q2]
2.58% less ownership
Funds ownership: 105.07% [Q1] → 102.5% (-2.58%) [Q2]
81% less call options, than puts
Call options by funds: $152K | Put options by funds: $788K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Sean Dodge 49% 1-year accuracy 22 / 45 met price target | 13%upside $12 | Outperform Maintained | 10 Sept 2024 |
Stephens & Co. Jacob Johnson 40% 1-year accuracy 6 / 15 met price target | 13%upside $12 | Overweight Reiterated | 10 Sept 2024 |
Financial journalist opinion
Based on 3 articles about CDMO published over the past 30 days